Table 1.
Viability of BCG (colony-forming units (cfu)) at each stage of matrix production (data represent mean ± SD, n = 3). For each matrix, 100 µL of BCG stock (1.48 ± 0.14 × 108 cfu/mL) was used, representing a starting BCG quantity of 1.5 × 107 cfu.
| Matrix 1 | Suspension (pH 7) | Freezing (−20 °C/6 h) | Freeze Drying (24 h) | Dry Powder Compaction | Matrix Exposure to SGF and SIF |
|---|---|---|---|---|---|
| A | 5.9 ± 0.4 × 105 | 5.5 ± 0.4 × 105 | 2.3 ± 0.7 × 105 | 2.0 ± 1.0 × 103 | 2.7 ± 0.1 × 103 |
| B | 6.1 ± 0.4 × 105 | 5.5 ± 1.1 × 105 | 7.0 ± 0.2 × 105 * | ND | 3.7 ± 0.3 × 103 |
| C | 6.5 ± 0.5 × 105 | 6.1 ± 0.5 × 105 | 6.5 ± 0.3 × 105 * | ND | 3.7 ± 0.2 × 103 |
1 BCG–Eudragit matrix composition: A, Eudragit L100/2 mL PBS/0.9 mL Tween® 80 (0.1% w/v); B, formulation A plus mannitol (0.2% w/v); C, formulation A plus trehalose (0.2% w/v). * p < 0.05 for pair-wise comparisons against matrix A.